Step Pharma
Vanessa Malier has been a Partner with Kurma Partners since 2013. Prior to joining Kurma, Vanessa was Vice President, R&D Strategic Planning at Ipsen, leading project and portfolio management as well as R&D outsourcing. She began her career as a venture analyst at CDC Innovation, a Paris-based venture capital fund, and later joined a California-based start-up with responsibility for business development. Vanessa graduated from Ecole Normale Superieure (Cachan) in Biology and from Pasteur Institute (Paris) in Immunology.
This person is not in the org chart
This person is not in any offices
Step Pharma
Step Pharma is developing a novel class of oral nucleotide synthesis inhibitors specifically targeting cytidine triphosphate synthase 1 (CTPS1) to induce selective modulation of T and B cell populations.